FDA Approves Novel Non-Opioid Pain Killer

Announcement Details

On January 30th, the United States Food and Drug Administration (FDA) announced the approval of a new non-opioid painkiller specifically designed for acute pain management.

Significance of Approval

Jacqueline Corrigan-Curay, J.D., M.D., the Acting Director of the FDA Center for Drug Evaluation and Research, emphasized the importance of this approval, stating, “Today’s approval is an important public health milestone in acute pain management. A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment option.” She further highlighted that this decision reflects the FDA’s commitment to facilitating the development and review of safe and effective alternatives to opioids for pain management.

About JOURNAVX™ (suzetrigine)

The newly approved drug, JOURNAVX™ (suzetrigine), developed by Vertex Pharmaceuticals Incorporated, is indicated for the treatment of severe to moderate pain in adults. It is priced at $15.50 per 50 mg pill in the United States. Unlike traditional opioids, JOURNAVX™ targets the neurons that transmit pain signals rather than acting on the brain, thereby reducing the risks of recreational use and addiction.

Industry Response

Reshma Kewalramani, M.D., the Chief Executive Officer and President of Vertex, expressed enthusiasm regarding the approval, stating, “With the approval of JOURNAVX, a non-opioid, pain signal inhibitor and the first new class of pain medicine approved in more than 20 years, we have the opportunity to change the paradigm of acute pain management and establish a new standard of care.”

Context of Approval

This development is particularly significant in light of ongoing efforts by healthcare authorities to reduce reliance on opioid-based painkillers in clinical practice.

Future Information

Further information regarding the efficacy and mechanism of JOURNAVX™ will be provided in subsequent communications.

References

– FDA. “FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain.” January 30, 2025. Accessed February 4, 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain
– Vertex Pharmaceuticals. “Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain.” Accessed February 4, 2025. https://news.vrtx.com/news-releases/news-release-details/vertex-announces-fda-approval-journavxtm-suzetrigine-first-class